doc_id,table_id,row_index,ColumnA,ColumnB,ColumnC
WHO_TB_handbook_module6_comorbidities_2024,Table 3.4,1,TB treatment regimens,Eligibility,Comments
WHO_TB_handbook_module6_comorbidities_2024,Table 3.4,2,6-month BPaLM / BPaL [ a ] regimen for MDR/RRTB and pre-XDR-TB,"All people, regardless of HIV status, except for people with TB involving the central nervous system, and osteoarticular and disseminated (miliary) TB","Caution should be used when enrolling individuals with CD4 counts less than 100 cells/mm 3 Efavirenz may induce the metabolism of bedaquiline; hence, an alternative antiretroviral agent should be used (potentially dolutegravir, although there is currently insufficient evidence for this)"
WHO_TB_handbook_module6_comorbidities_2024,Table 3.4,3,9-month all-oral regimen for MDR/ RR-TB [ b ],"People with drug-resistant TB, regardless of HIV status, and: No documented resistance to drugs included in regimen No exposure to previous treatment with bedaquiline, fluoroquinolones, clofazimine, or ethionamide or linezolid for >1 month No extensive or severe TB disease and no severe extrapulmonary disease","Efavirenz can reduce the concentration of bedaquiline; therefore, this antiretroviral drug should be avoided in individuals receiving the 9-month all-oral regimen There are no overlapping toxicities or drug–drug interactions with dolutegravir in individuals receiving the shorter regimen with either linezolid or ethionamide"
WHO_TB_handbook_module6_comorbidities_2024,Table 3.4,4,Individualized longer regimen designed using the priority grouping of medicines recommended in current WHO guidelines,People with extensive forms of DR-TB (e.g. XDR-TB) or those who are not eligible for or have had no response to shorter treatment regimens,"Drug–drug interactions and adverse events need to be carefully considered and monitored, depending on the TB treatment and ART regimens prescribed"